Stockscreener 앱 받기
3.10
3.13%
-0.10
시간 외 거래:
3.22
0.12
+3.87%
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks
Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo
Cellectar (NASDAQ: CLRB) S-1 details 51.2M-share resale and major warrant overhang - Stock Titan
Cellectar Biosciences Announces Board Changes and New Director - TipRanks
Cellectar Biosciences (NASDAQ: CLRB) seeks approval for warrants and plan increase - Stock Titan
Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant - TradingView
Cellectar (NASDAQ: CLRB) reshapes board with Loren exit and Andrew Gu appointment - Stock Titan
User | dailytimesleader.comCellectar Biosciences, Inc.Common Stock (Nasdaq:CLRB) Stock Quote - FinancialContent
Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia - MSN
CLRB Assumed by Ladenburg Thalmann -- Rating Set to Buy - GuruFocus
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing - Minichart
Cellectar Biosciences, Inc.Common Stock (NQ: CLRB - FinancialContent
What's Going With Cellectar Biosciences Stock On Wednesday? - MSN
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Cellectar Biosciences Signals Pivotal Turn in Earnings Call - TipRanks
Cellectar Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Cellectar Biosciences (CLRB) Reports Positive Phase IIb Results and Plans FDA Filing - GuruFocus
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences, Inc. Q1 2026 Financial Report, Forward-Looking Statements, and SEC Filings - Minichart
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Cellectar plans phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 - MSN
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress - Investing.com UK
Is Cellectar Biosciences (CLRB) Attractively Valued After Q1 202 - GuruFocus
Cellectar Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress By Investing.com - Investing.com Nigeria
CLRB: Strong clinical results and $140M financing drive late-stage execution and regulatory momentum - TradingView
Cellectar (CLRB) Secures $140 Million Financing for Regulatory M - GuruFocus
Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call - Benzinga
Cellectar Biosciences 1Q Loss $5.65M >CLRB - Moomoo
CLRB: Strong efficacy in r/r WM and robust financing position clinical programs for key milestones - TradingView
Cellectar Biosciences reports Q1 2026 net loss of $5.65M; cash $8.3M before $31M financing - TradingView
Cellectar Biosciences (CLRB) posts Q1 2026 loss and secures up to $140M - Stock Titan
Cellectar Biosciences, Inc. Q1 2026: Net loss $(5.65M), EPS $(1.33) — 10-Q Summary - TradingView
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cellectar Biosciences (NASDAQ: CLRB) posts Q1 loss and flags going-concern risk - Stock Titan
CLRB: Net loss narrowed, clinical data for iopofosine I 131 remained strong, and $35M was raised for Phase 3 - TradingView
Cellectar Biosciences Inc expected to post a loss of $1.88 a shareEarnings Preview - TradingView
Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock - Investing.com UK
Cellectar Biosciences CEO buys $24,998 in company stock - Investing.com UK
Cellectar Biosciences CEO buys $24,998 in company stock By Investing.com - Investing.com South Africa
Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock By Investing.com - Investing.com Canada
Cellectar (NASDAQ: CLRB) COO boosts stake with common stock and warrant buys - Stock Titan
Cellectar (CLRB) CEO reports open-market stock and warrant buys - Stock Titan
Stonepine, Jon Plexico disclosed 9.9% stake in Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 - Investing News Network
0.98%
0.12%
자본화:
|
볼륨(24시간):